Compare SUNB & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SUNB | ROIV |
|---|---|---|
| Founded | 1947 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.2B | 28.7B |
| IPO Year | 2025 | 2021 |
| Metric | SUNB | ROIV |
|---|---|---|
| Price | $81.45 | $41.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 13 |
| Target Price | ★ $88.97 | $49.91 |
| AVG Volume (30 Days) | 3.2M | ★ 7.2M |
| Earning Date | 12-23-2026 | 11-09-2026 |
| Dividend Yield | ★ 1.47% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.07 | N/A |
| Revenue | ★ $11,154,000,000.00 | $8,260,000.00 |
| Revenue This Year | $7.93 | $562.28 |
| Revenue Next Year | $7.43 | $734.15 |
| P/E Ratio | $76.78 | ★ N/A |
| Revenue Growth | ★ 3.36 | N/A |
| 52 Week Low | $61.03 | $19.96 |
| 52 Week High | $86.68 | $42.50 |
| Indicator | SUNB | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 55.79 | 66.22 |
| Support Level | $71.10 | $33.11 |
| Resistance Level | $85.79 | $42.50 |
| Average True Range (ATR) | 3.02 | 1.52 |
| MACD | -0.27 | 0.53 |
| Stochastic Oscillator | 59.36 | 94.46 |
Sunbelt Rentals (formerly UK-based Ashtead Group) is the number two equipment rental company in the US (11% market share), with a smaller presence in Canada and the UK. Sunbelt operates a rental fleet of just over $20 billion across a network of 1,200 stores in the US, nearly 135 stores in Canada, and and 190 stores in the UK. The company has experienced rapid growth over the past decade as its customers increasingly turn to rental versus owning equipment outright. The general tool business has been augmented by the Specialty Rental business, which has grown to 30% of the mix. Revenue is now greater than 50% nonconstruction, with the remainder focused more directly on commercial construction.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.